On Tuesday, the FDA Oncologic Drugs Advisory Committee voted 12-1 to recommend that the agency revoke approval of Avastin for the treatment of breast cancer, citing sparse evidence that the drug benefited patients in two new studies, the New York Times reports (Pollack, New York Times, 7/20)...
More...